U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H12N2O8.Cu.2Na
Molecular Weight 397.736
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DISODIUM EDTA-COPPER

SMILES

[Na+].[Na+].[Cu++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O

InChI

InChIKey=KCFCAUKZKOSSBI-UHFFFAOYSA-J
InChI=1S/C10H16N2O8.Cu.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;+2;2*+1/p-4

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H12N2O8
Molecular Weight 288.2109
Charge -4
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Determination of protein by the biuret reaction using cupric hydroxide suspension reagent.
1960
Efficacy of burning, tillage, and biocides in controlling bacteria released at field sites and effects on indigenous bacteria and fungi.
1992 Apr
The genetics of tasting in mice. VII. Glycine revisited, and the chromosomal location of Sac and Soa.
1995 Oct
Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers.
2000 Jul
The effectiveness of ecologically acceptable ways of protection of field-grown tomato (Lycopersicon lycopersicum (L.) Karsten) from tomato late blight (Phytophthora infestans (Mont.) de Bary) in extreme weather conditions.
2001
Cu(II) acetate- and Mn(III) acetate-mediated radical reactions of [60]fullerene with ketonic compounds.
2005 Mar 7
Acute copper toxicity following copper glycinate injection.
2006 Nov
Enhanced copper release from pipes by alternating stagnation and flow events.
2007 Nov 1
Bioavailability of copper from copper glycinate in steers fed high dietary sulfur and molybdenum.
2008 Jan
Synthesis and structural investigation of mono- and polynuclear copper complexes of 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide.
2008 Nov 1
Insight in the transport behavior of copper glycinate complexes through the porcine gastrointestinal membrane using an Ussing chamber assisted by mass spectrometry analysis.
2010 Apr
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.
2010 Feb 3
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.
2011 Apr
Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis.
2011 Dec 27
Rapid free chlorine decay in the presence of Cu(OH)2: chemistry and practical implications.
2011 Oct 15
Expeditious synthesis of phenanthrenes via CuBr2-catalyzed coupling of terminal alkynes and N-tosylhydrazones derived from o-formyl biphenyls.
2011 Oct 7
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
CuBr2--a new multiferroic material with high critical temperature.
2012 May 8
Evaluation of topically applied copper(II) oxide nanoparticle cytotoxicity in human skin organ culture.
2013 Feb
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.
2013 Jan 18
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
2013 May
Molecular responses of mouse macrophages to copper and copper oxide nanoparticles inferred from proteomic analyses.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.
2013 Oct 24
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Synthesis and biomedical applications of copper sulfide nanoparticles: from sensors to theranostics.
2014 Feb 26
Electron induced surface reactions of organometallic metal(hfac)₂ precursors and deposit purification.
2014 Jun 11
CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin.
2015 Jun
A Facile Strategy for Catalyst Separation and Recycling Suitable for ATRP of Hydrophilic Monomers Using a Macroligand.
2016 Jan
Dissecting copper homeostasis in diabetes mellitus.
2017 Apr
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Roles of Copper-Binding Proteins in Breast Cancer.
2017 Apr 20
Supplementation with copper edetate in control of Haemonchus contortus of sheep, and its effect on cholinesterase's and superoxide dismutase activities.
2017 Feb
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis.
2017 Jul
Folic acid-modified and functionalized CuS nanocrystal-based nanoparticles for combined tumor chemo- and photothermal therapy.
2017 Jun
Amino acid-mediated 'turn-off/turn-on' nanozyme activity of gold nanoclusters for sensitive and selective detection of copper ions and histidine.
2017 Jun 15
Effects of Excess Copper Ions on Decidualization of Human Endometrial Stromal Cells.
2017 May
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:24:04 UTC 2023
Edited
by admin
on Fri Dec 15 16:24:04 UTC 2023
Record UNII
6V475AX06U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DISODIUM EDTA-COPPER
INCI  
INCI  
Official Name English
DISODIUM (N,N'-1,2-ETHANEDIYLBIS(N-(CARBOXYMETHYL)GLYCINATO) (4-)-N,N',O,O',O(SUP N), O(SUP N')) CUPRATE (2-)
Common Name English
COPPER VERSENATE
Common Name English
CUPRATE(2-), ((N,N'-1,2-ETHANEDIYLBIS(N-((CARBOXY-.KAPPA.O)METHYL)GLYCINATO-.KAPPA.N,.KAPPA.O))(4-))-, SODIUM (1:2), (OC-6-21)-
Common Name English
COPPER DISODIUM EDETATE
Systematic Name English
COPPER DISODIUM ETHYLENEDIAMINETETRAACETATE
Systematic Name English
DISODIUM EDTA-COPPER [INCI]
Common Name English
NSC-7346
Code English
BOVI-CU
Brand Name English
Code System Code Type Description
SMS_ID
300000033158
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
FDA UNII
6V475AX06U
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
PUBCHEM
51964
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
RXCUI
1366887
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY RxNorm
NSC
7346
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
DRUG BANK
DB14599
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
ECHA (EC/EINECS)
237-864-5
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
DAILYMED
6V475AX06U
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
CAS
14025-15-1
Created by admin on Fri Dec 15 16:24:04 UTC 2023 , Edited by admin on Fri Dec 15 16:24:04 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY